ArticleFrontiers in veterinary science2025
Foot-and-mouth disease virus-like particle vaccine incorporating dominant T and B cell epitopes: enhanced immune response in piglets with CD154 molecules.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of the effectiveness of polypeptide, virus-like particles, and viral vector vaccines for foot-and-mouth disease (2020-2025).Scientific reports · 2025Pooled it
- Evolutionary and structural insights into VP1 epitopes of representative SAT-type FMDV strains: implications for candidate vaccine selection.Veterinary research · 2025Review
- Virus-like particle-based liquid phase blocking ELISA for evaluating the efficacy of O-type foot-and-mouth disease vaccines.Applied microbiology and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Foot-and-mouth disease (FMD) is a highly contagious disease caused by FMDV, resulting in vesicular lesions in cloven-hoofed animals and posing significant economic threats to the livestock industry. VLP vaccines, which lack viral genetic material and are non-infectious, demonstrate superior safety compared to traditional inactivated vaccines. This study employs ADDomer, a novel adenovirus-based VLP framework, to display FMDV antigenic epitopes on the VLP surface. Additionally, FMDV capsid proteins can assemble into VLPs, offering innovative approaches for developing more efficient and safer FMDV vaccines. Methods: Two FMDV VLP proteins were constructed using a baculovirus expression system. One VLP was developed by embedding the B-cell epitope of FMDV VP1 into the G-H loop of VP3 and co-expressing it with VP1 and VP0 to form VP1-VP3 Results: After purification, both VLPs displayed virus-like structures under electron microscopy. Immunization in piglets induced high levels of FMDV-specific and neutralizing antibodies, enhanced cytokines IL-2, IL-4, and IFN-γ, and increased lymphocyte proliferation. The CD154-added group showed higher immune responses. Discussion: The VLP vaccines effectively induced strong cellular and humoral immune responses, with CD154 enhancing efficacy. These findings provide insights for developing safer, more effective FMDV vaccines and contribute to advancing livestock health and productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.